GlassScriptPhysician profile
Kevin L Oltmanns
NPI 1316926728
$3,060.06
in general payments reported to CMS, 2019-2025
30 companies · $225 in 2025
The $225 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,037 · 2020: $132 · 2021: $564 · 2022: $466 · 2023: $313 · 2024: $323 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $861.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $861.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $473.53 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Astrazeneca Pharmaceuticals LP | $371.90 | 2019-2022 | |
| Pfizer INC. | $359.31 | 2019-2025 | |
| Amarin Pharma, INC. | $262.25 | 2019-2021 | |
| Abbott Laboratories | $213.12 | 2021-2024 | Freestyle Libre 3 |
| Abbvie INC. | $176.46 | 2021-2025 | |
| Portola Pharmaceuticals, LLC | $143.78 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.03 | 2019-2022 | |
| Astellas Pharma US INC | $132.62 | 2019-2025 | Veozah |
| Amgen INC. | $108.31 | 2019-2021 | |
| Mylan Specialty L.P. | $85.01 | 2021 | |
| Glaxosmithkline, LLC. | $62.56 | 2022-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $59.87 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $56.73 | 2019-2025 | Wegovy |
| Ultragenyx Pharmaceutical INC. | $45.41 | 2021-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $44.06 | 2025 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $40.27 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.22 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $40.12 | 2019-2024 | Spravato |
| Ferring Pharmaceuticals INC. | $33.89 | 2024-2025 | Rebyota |
| Harmony Biosciences LLC | $26.56 | 2021 | |
| Madrigal Pharmaceuticals | $25.32 | 2024 | Resmetirom |
| Idorsia Pharmaceuticals US INC | $18.47 | 2023 | Quviviq |
| Antares Pharma, INC. | $16.88 | 2022 | |
| Merck Sharp & Dohme LLC | $16.52 | 2024 | Vaxneuvance, Vaxelis, Capvaxive |
| Biohaven Pharmaceutical Holding Company LTD. | $15.99 | 2022 | |
| Corium, LLC | $15.91 | 2022 | |
| Dexcom, INC. | $14.57 | 2023 | Dexcom G6 Transmitter |
| Hologic Sales and Service, LLC | $11.73 | 2022 | |
| Medtronic USA, INC. | $11.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Oltmanns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.